A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.
ClinicalTrials.gov Identifier:
NCT01520727
First received: January 18, 2012
Last updated: December 29, 2014
Last verified: December 2014
  Purpose

The purpose of this study was to investigate the safety, tolerability, pharmacokinetics and catechol-O-methyltransferase (COMT) activity of BIA 9-1067 in healthy male subjects after single oral ascending doses.


Condition Intervention Phase
Parkinson Disease
Drug: BIA 9-1067
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects

Resource links provided by NLM:


Further study details as provided by Bial - Portela C S.A.:

Primary Outcome Measures:
  • Adverse Events (AEs) [ Time Frame: 7 weeks ] [ Designated as safety issue: Yes ]
    Safety was evaluated from the number of reported adverse events (AEs)


Secondary Outcome Measures:
  • Cmax - BIA 9-1067 [ Time Frame: pre-dose then post-dose. Hour 0.25, 0.5, 0,75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 , 60 and 72 hours post dose ] [ Designated as safety issue: Yes ]
    Cmax - maximum plasma concentration

  • Time to Cmax (Tmax) [ Time Frame: pre-dose then post-dose. Hour 0.25, 0.5, 0,75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 , 60 and 72 hours post dose ] [ Designated as safety issue: Yes ]

Enrollment: 64
Study Start Date: October 2007
Study Completion Date: April 2009
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIA 9-1067 10 mg
BIA 9-1067 (Opicapone, OPC) - 10 mg
Drug: BIA 9-1067
single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Other Name: Entacapone
Experimental: BIA 9-1067 25 mg
BIA 9-1067 (Opicapone, OPC) - 25 mg
Drug: BIA 9-1067
single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Other Name: Entacapone
Experimental: BIA 9-1067 50 mg
BIA 9-1067 (Opicapone, OPC) - 50 mg
Drug: BIA 9-1067
single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Other Name: Entacapone
Experimental: BIA 9-1067 100 mg
BIA 9-1067 (Opicapone, OPC) - 100 mg
Drug: BIA 9-1067
single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Other Name: Entacapone
Experimental: BIA 9-1067 200 mg
BIA 9-1067 (Opicapone, OPC) - 200 mg
Drug: BIA 9-1067
single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Other Name: Entacapone
Experimental: BIA 9-1067 400 mg
BIA 9-1067 (Opicapone, OPC) - 400 mg
Drug: BIA 9-1067
single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Other Name: Entacapone
Experimental: BIA 9-1067 800 mg
BIA 9-1067 (Opicapone, OPC) - 800 mg
Drug: BIA 9-1067
single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Other Name: Entacapone
Experimental: BIA 9-1067 1200 mg
BIA 9-1067 (Opicapone, OPC) - 1200 mg
Drug: BIA 9-1067
single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Other Name: Entacapone
Placebo Comparator: Placebo
Placebo (PLC): single-dose
Drug: Placebo
single-dose
Other Name: Placebo

Detailed Description:

Single centre, randomised, double-blind, placebo-controlled study of single ascending doses in up to 8 sequential groups of 8 healthy young male subjects.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A signed and dated informed consent form before any study-specific screening procedure was performed.
  • Aged between 18 and 45 years, inclusive.
  • Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and digital 12-lead ECG.
  • Non-smoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.

Exclusion Criteria:

  • Any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory (e.g. childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia), immunologic, dermatological, haematological, neurologic, or psychiatric disease.
  • Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before study day 1.
  • History of drug abuse within 1 year before study day 1.
  • History of alcoholism within 1 year before day 1. Consumption of more than 50 g of ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%] whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15 g
  • Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.
  • Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, MDMA [3,4-methylenedioxy-methamphetamine; ecstasy]).
  • History of any clinically important drug allergy.
  • Prohibited Treatments: use of any investigational drug within 90 days or prescription drug within 30 days before investigational medical product (IMP) administration.
  • Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or soda) in excess of 6 cups per day (or equivalent), of grapefruit, grapefruit-containing products, or alcoholic beverages within 24 hours before study day 1.
  • Use of any over-the-counter drugs including herbal supplements (except for the occasional use of acetaminophen [paracetamol], aspirin and vitamins ≤100% recommended daily allowance) within 7 days before IMP administration.
  • Donation of blood (i.e. 450 mL) within 60 days before study day 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01520727

Locations
France
BIOTRIAL
Rennes, France, F-35000
Sponsors and Collaborators
Bial - Portela C S.A.
Investigators
Principal Investigator: Nicolas Fauchoux, MD BIOTRIAL
  More Information

No publications provided

Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT01520727     History of Changes
Other Study ID Numbers: BIA-91067-101
Study First Received: January 18, 2012
Results First Received: December 29, 2014
Last Updated: December 29, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Bial - Portela C S.A.:
BIA 9-1067

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders

ClinicalTrials.gov processed this record on May 21, 2015